Clinical trials: Thyroid Eye Disease, TED, open to volunteers
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain.
- Conditions
- Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy
- Trial name
- TOFA-GO (NCT07547930)
- Testing
- Tofacitinib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
- Trial name
- NCT07620405
- Testing
- MHB018A injection
- Volunteers
- 219 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy
This study aims to evaluate the efficacy and safety of sequential Teprotumumab N01 compared with intravenous methylprednisolone (IVMP) after urgent orbital decompression in patients with dysthyroid optic neuropathy (DON).
- Conditions
- Thyroid Eye Disease, TED, Graves Ophthalmopathy, Optic Neuropathy
- Trial name
- NCT07594912
- Testing
- Teprotumumab N01, Intravenous Methylprednisolone (IVMP)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Thyroid Eye Disease (TED), Graves' Disease
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.
- Conditions
- Thyroid Eye Disease (TED), Graves' Disease, Eye Diseases, Hereditary, Eye Diseases
- Trial name
- NCT07885605
- Testing
- ETHY-001
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ethyreal Bio, Inc.
Graves' Orbitopathy, Thyroid Eye Disease, TED
Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' Disease
The aim of this observational study is to investigate why some people with newly diagnosed Graves' disease (GD) develop thyroid eye disease (TED), also known as Graves' orbitopathy, while others do not.
- Conditions
- Graves' Orbitopathy, Thyroid Eye Disease, TED, Graves' Disease
- Trial name
- SOGO (NCT07812194)
- Testing
- Study-related ophthalmological assessment and biospecimen collection, Blood biomarkers and standardized blood samples including thyroid function status
- Where
- Denmark
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Thyroid Eye Disease
Transconjunctival Versus Transcutaneous Betamethasone for Upper Eyelid Retraction in TED
This randomized controlled trial aims to compare the efficacy and safety of transconjunctival versus transcutaneous perilevator betamethasone injection in reducing upper eyelid retraction in patients with thyroid eye disease.
- Trial name
- NCT07866261
- Testing
- Betamethasone
- Volunteers
- 54 people
- Sponsor
- Assiut University
Thyroid Eye Disease, TED
A Clinical Study of Cizutamig in Thyroid Eye Disease
The purpose of this study is to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with thyroid eye disease (TED).
- Trial name
- NCT07597200
- Testing
- Cizutamig will be dosed according to the protocol.
- Where
- 14 sites in China
- Volunteers
- 38 people
- Sponsor
- Candid Therapeutics
Thyroid Eye Disease, Graves Ophthalmopathy
Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease
The trial tests the hypothesis that, in adults with active, moderate-to-severe Graves' orbitopathy, 24 weeks of oral atorvastatin 20 mg daily added to a standard 12-week course of intravenous methylprednisolone produces a greater…
- Conditions
- Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy
- Trial name
- SEMAR-TED (NCT07762105)
- Testing
- Atorvastatin, methylprednisolone (IVMP)
- Where
- Indonesia
- Volunteers
- 64 people
- Sponsor
- Banu Aji Dibyasakti
Thyroid Eye Disease, Graves Orbitopathy
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24.
- Conditions
- Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases
- Trial name
- NCT06112340
- Testing
- linsitinib
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Sling Therapeutics, Inc.
Thyroid Eye Disease, Thyroid Eye Disease, TED
Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease
The goal of this interventional study is to compare the clinical outcomes of shortened 4-infusion course versus the standard 8-infusion course of Teprotumumab (Tepezza) in patients with active Thyroid Eye Disease (TED).
- Conditions
- Thyroid Eye Disease, Thyroid Eye Disease, TED, Thyroid Eye Disease (TED)
- Trial name
- NCT07308964
- Testing
- Teprotumumab Injection [Tepezza]
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Graves Ophthalmopathy, Graves Disease
Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE National Multicenter Registry Study
The goal of this observational study is to prospectively validate the efficacy of an AI multimodal model constructed based on multi - sequence orbital MRI in the diagnosis, activity and severity assessment, and prognosis…
- Conditions
- Graves Ophthalmopathy, Graves Disease, Thyroid Associated Ophthalmopathies
- Trial name
- TED-SCOPE-MR (NCT07716397)
- Testing
- MRI scan，ocular ultrasound
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
Thyroid Eye Disease
A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled Phase 3 study to evaluate the efficacy, safety, immunogenicity, and population pharmacokinetic (PopPK) characteristics of KHN939 in Chinese patients with…
- Trial name
- Halo-1 (NCT07720635)
- Testing
- KHN939
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Kanghong Biological Medicine Co., Ltd.
Thyroid Eye Disease, TED
Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study
The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with active moderate-to-severe TED.
- Trial name
- NCT07622108
- Testing
- MHB018A
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Thyroid Associated Ophthalmopathies
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT07152392
- Testing
- IBI311, Follew-up
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Changzheng Hospital
Thyroid Associated Ophthalmopathies
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter…
- Trial name
- NCT07152340
- Testing
- IBI311, Glucocorticoids
- Where
- 2 sites in China
- Volunteers
- 64 people
- Sponsor
- Shanghai Changzheng Hospital
Thyroid Eye Disease, TED
Treatment of Chronic Thyroid Eye Disease With MHB018A
The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with chronic moderate-to-severe TED.
- Trial name
- NCT07622121
- Testing
- MHB018A injection
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Thyroid Eye Disease (TED)
A Study of VV-14305 for the Treatment of Thyroid Eye Disease
The goal of this study is to evaluate the safety, tolerability, and efficacy of KRIYA-586 (VV-14305) in treating thyroid eye disease (TED).
- Trial name
- RECLAIM (NCT07404111)
- Testing
- VV-14305
- Where
- 5 sites in United States, New Zealand
- Volunteers
- 135 people
- Sponsor
- Kriya Therapeutics, Inc.
Thyroid Eye Disease (TED), Graves Ophthalmopathy
Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE)
This prospective observational study evaluates the feasibility and clinical utility of a smartphone-based artificial intelligence (AI) self-monitoring system in adults with thyroid eye disease (TED) undergoing non-surgical…
- Conditions
- Thyroid Eye Disease (TED), Graves Ophthalmopathy, Thyroid Associated Ophthalmopathies
- Trial name
- THYROSCOPE-TED (NCT07623993)
- Testing
- Smartphone-based AI self-monitoring application (Glandy CAS/EXO/LID)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- THYROSCOPE INC.
Graves Disease, Graves Disease (Basedow's Disease)
Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)
Graves' disease is an autoimmune condition that causes an overactive thyroid. Some people with Graves' disease develop thyroid eye disease, also called Graves' orbitopathy, which can cause swelling around the eyes, eye…
- Conditions
- Graves Disease, Graves Disease (Basedow's Disease), Graves Orbitopathy, Graves Ophthalmopathy
- Trial name
- ATORGO (NCT07883356)
- Testing
- Atorvastatin
- Where
- 7 sites in Sweden
- Volunteers
- 554 people
- Sponsor
- Region Skane
Safety, Tolerability
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
To evaluate the safety and tolerability of single and multiple ascending subcutaneous doses of GenSci098 in patients with thyroid eye disease (TED)
- Conditions
- Safety, Tolerability, GenSci098, Thyroid Eye Disease (TED)
- Trial name
- NCT06569758
- Testing
- GenSci098
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.